The effect of interferon beta-1a treatment on adaptability of the brai
The effect of interferon beta-1a treatment on functional adaptation in Multiple Sclerosis (MS)
What it found
We found no results in the registry or in papers.
What was tested
Compared with
- Interferon beta-1a
Interferon alpha/beta receptor agonist
What it measured
Main measures
Primary Endpoints: The mean change of each subject affected by RRMS or relapsing SPMS from baseline in functional connectivity (resting-state) fMRI at month 24.
Nerve conduction tests
Other measures (1)
Secondary Endpoints: Clinicial measures (progression of disability) will be measured through change in Extended Disability Status Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC). Clinical measures (progression of disease activity) as measured through the number of relapses and annualized relapse rate. Cognitive decline as measured by change in Brief Repeatable Battery – Neuropsycho
Disability progressionRelapsesThinking and memoryNerve conduction tests
Who could take part
MS (type not specified)
Show the full criteria
Inclusion criteria
Inclusion: age 18-65 Exclusion: MS other than RRMS or relapsing SPMS
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Primary: Does immunomodulation brought about by interferon beta-1a (Rebif) enhance or prolong functional reorganization in subjects with RRMS?
Loading reviews and guidelines…
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
Started
Nov 2011